Benzinga | Oct 29, 2020 12:07PM EDT

Why ChemoCentryx's Stock Is Trading Lower Today

ChemoCentryx (NASDAQ:CCXI) shares are trading lower on Thursday after the company announced topline data from its Phase II AURORA clinical trial of Avacopan in the treatment of Hidradenitis Suppurativa.

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer.

ChemoCentryx shares were trading down 6.90% at $48.64 on Thursday. The stock has a 52-week high of $65.43 and a 52-week low of $7.88.